Most Read

With this expansion and added production line, the company can now offer more plasmid material in quality and GMP grades as well as extend the mRNA supply services.

The multicentre, open-label study will evaluate the autologous fully human anti-cd19 chimeric antigen receptor (CAR) T cell therapy KYV-101 in adult scleroderma patients. Kyverna Therapeutics CEO Peter Maag

The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not

CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are

LIVMARLI is claimed to be the first and only approved therapy in Taiwan used for treating cholestatic pruritus in patients with ALGS aged one year or older. Recently,

The 35,000ft2 facility, located inside the Ziggurat building, includes a cold chain, a warehousing, two single-use drug substance lines (50L and 500L scale HyPerforma DynaDrive), a buffer and

Kurma Partners’ Growth Opportunities Fund led the funding round, which has also seen participation from existing investors including Enterprise Ireland, Seroba Life Sciences, and Irish, US and Canadian

BBP-812 and BBP-631 are the lead assets of BridgeBio. An adeno-associated virus (AAV) 9 gene therapy, BBP-812 is intended to treat Canavan disease while BBP-631 is an AAV

With an investment of $38m, the company has doubled the manufacturing capacity of the facility. The expansion included new advanced analytical and chemical development laboratories and construction of